{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T10:16:16Z","timestamp":1788344176954,"version":"build-2803163510"},"reference-count":30,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T00:00:00Z","timestamp":1788307200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:p>Hospice care centers on interdisciplinary-driven, patient-focused, comprehensive and individualized care at the end of life. Effective pain management has been a cornerstone of hospice care, with up to 80% of patients experiencing moderate to severe pain at the end of life. Although central to hospice care, opioid prescribing faces major challenges: wide variability in response, frequent adverse effects (sedation, constipation, respiratory depression, cognitive impairment), and high rates of uncontrolled pain (20%\u201340% of patients inadequately relieved despite optimization). Traditional trial-and-error approaches are challenging in hospice due to short prognoses, complex comorbidities, and prevalent polypharmacy. Supportive evidence for the inclusion of Pharmacogenomics (PGx) testing into opioid prescribing is growing. Incorporating PGx testing into opioid prescribing practices at the end of life will face several hurdles including shifting protocols, cost of testing, and ethical concerns. With policy reforms, prescriber training, and rigorous research, PGx may become a useful tool in delivering truly personalized end-of-life care.<\/jats:p>","DOI":"10.3389\/fmed.2026.1920877","type":"journal-article","created":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T09:39:51Z","timestamp":1788341991000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Pharmacogenomic-guided opioid prescribing in hospice: reducing toxicity while maximizing symptom relief"],"prefix":"10.3389","volume":"13","author":[{"given":"Ben","family":"Thompson","sequence":"first","affiliation":[{"name":"Gentiva","place":["Atlanta, GA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carrie","family":"Hyde","sequence":"additional","affiliation":[{"name":"Gentiva","place":["Atlanta, GA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Binoy","family":"Singh","sequence":"additional","affiliation":[{"name":"Gentiva","place":["Atlanta, GA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,2]]},"reference":[{"key":"ref1","year":"2026"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"1943","DOI":"10.1056\/NEJMra025411","article-title":"Opioid therapy for chronic pain","volume":"349","author":"Ballantyne","year":"2003","journal-title":"N Engl J Med"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"2549","DOI":"10.1056\/NEJMra1411746","article-title":"Comfort care for patients dying in the hospital","volume":"373","author":"Blinderman","year":"2015","journal-title":"N Engl J Med"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1089\/jpm.2015.0039","article-title":"Is care for the dying improving in the United States?","volume":"18","author":"Teno","year":"2015","journal-title":"J Palliat Med"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"2948","DOI":"10.1200\/JCO.21.00476","article-title":"US trends in opioid access among patients with poor prognosis cancer near the end-of-life","volume":"39","author":"Enzinger","year":"2021","journal-title":"J Clin Oncol"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"e55","DOI":"10.1016\/j.jpainsymman.2025.03.031","article-title":"Medications reported to the medicare hospice program after medicare drug policy changes, 2014\u20132018","volume":"70","author":"Tjia","year":"2025","journal-title":"J Pain Symptom Manag"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"2211","DOI":"10.1056\/NEJMra032424","article-title":"Drug metabolism and variability among patients in drug response","volume":"352","author":"Wilkinson","year":"2005","journal-title":"N Engl J Med"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1016\/j.jmoldx.2021.05.013","article-title":"Recommendations for clinical CYP2D6 genotyping allele selection","volume":"23","author":"Pratt","year":"2021","journal-title":"J Mol Diagn"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"e2558299","DOI":"10.1001\/jamanetworkopen.2025.58299","article-title":"CYP2D6-guided opioid management and postoperative pain control: a randomized clinical trial","volume":"9","author":"Cavallari","year":"2026","journal-title":"JAMA Netw Open"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1111\/j.1476-5381.2010.00673.x","article-title":"The effects of CYP2D6 and CYP3A activities on the pharmacokinetics of immediate release oxycodone","volume":"160","author":"Samer","year":"2010","journal-title":"Br J Pharmacol"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/j.bcp.2018.02.020","article-title":"Effects of cytochrome P450 single nucleotide polymorphisms on methadone metabolism and pharmacodynamics","volume":"153","author":"Ahmad","year":"2018","journal-title":"Biochem Pharmacol"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1097\/ALN.0000000000000867","article-title":"Methadone pharmacogenetics","volume":"123","author":"Kharasch","year":"2015","journal-title":"Anesthesiology"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.pain.2005.03.032","article-title":"The VAL158MET polymorphism of the human catechol-O-methyltransferase (COMT) gene may influence morphine requirements in cancer pain patients","volume":"116","author":"Rakv\u00e5g","year":"2005","journal-title":"Pain"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"112060","DOI":"10.1016\/j.biopha.2021.112060","article-title":"Reviewing pharmacogenetics to advance precision medicine for opioids","volume":"142","author":"Magarbeh","year":"2021","journal-title":"Biomed Pharmacother"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"331","DOI":"10.36076\/ppj\/2019.22.331","article-title":"The relevance of the oprm1 118A>g genetic variant for opioid requirement in pain treatment: a meta-analysis","volume":"4","author":"Chu","year":"2019","journal-title":"Pain Physician"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1016\/j.jpain.2014.09.002","article-title":"How much oxycodone is needed for adequate analgesia after breast cancer surgery: effect of the oprm1 118A>G polymorphism","volume":"15","author":"Cajanus","year":"2014","journal-title":"J Pain"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1089\/jpm.2021.0270","article-title":"Feasibility and acceptability of a pharmacogenomic decision support system in palliative care","volume":"25","author":"Bull","year":"2022","journal-title":"J Palliat Med"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1038\/sj.clpt.6100152","article-title":"Concentrations of tramadol and O-desmethyltramadol enantiomers in different CYP2D6 genotypes","volume":"82","author":"Stamer","year":"2007","journal-title":"Clin Pharmacol Ther"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1016\/S0025-6196(11)60750-7","article-title":"Opioid metabolism","volume":"84","author":"Smith","year":"2009","journal-title":"Mayo Clin Proc"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"e2523543","DOI":"10.1001\/jamanetworkopen.2025.23543","article-title":"CYP2D6 phenotypes and emergency department visits among patients receiving opioid treatment","volume":"8","author":"Nahid","year":"2025","journal-title":"JAMA Netw Open"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1136\/spcare-2024-005205","article-title":"Pharmacogenomics and symptom management in palliative and supportive care: a scoping review","volume":"15","author":"Barry","year":"2025","journal-title":"BMJ Support Palliat Care"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"5927","DOI":"10.1007\/s00520-021-06170-4","article-title":"Potentially actionable pharmacogenetic variants and symptom control medications in oncology","volume":"29","author":"Patel","year":"2021","journal-title":"Support Care Cancer"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"15952","DOI":"10.1523\/JNEUROSCI.1609-13.2013","article-title":"Blockade of toll-like receptor 4 attenuates morphine tolerance and facilitates the pain relieving properties of morphine","volume":"33","author":"Eidson","year":"2013","journal-title":"J Neurosci"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"901","DOI":"10.2217\/pgs-2023-0207","article-title":"Effect of gene variants on opioid dose, pain and adverse effect outcomes in advanced cancer: an explorative study","volume":"24","author":"Wong","year":"2009","journal-title":"Pharmacogenomics"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"1342515","DOI":"10.3389\/fphar.2024.1342515","article-title":"Physiologically based pharmacokinetic modeling to predict the pharmacokinetics of codeine in different CYP2D6 phenotypes","volume":"15","author":"Yang","year":"2024","journal-title":"Front Pharmacol"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"e2042","DOI":"10.1002\/onco.13953","article-title":"Impact of cyp2d6 pharmacogenomic status on pain control among opioid-treated oncology patients","volume":"26","author":"Reizine","year":"2021","journal-title":"Oncologist"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"1179364","DOI":"10.3389\/fphar.2023.1179364","article-title":"Reimbursement of pharmacogenetic tests at a tertiary Academic Medical Center in the United States","volume":"14","author":"Lemke","year":"2023","journal-title":"Front Pharmacol"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1097\/FPC.0000000000000061","article-title":"Cancer patients\u2019 acceptance, understanding, and willingness-to-pay for pharmacogenomic testing","volume":"24","author":"Cuffe","year":"2014","journal-title":"Pharmacogenet Genomics"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1177\/0269216319854944","article-title":"The incidence and prevalence of delirium across palliative care settings: a systematic review","volume":"33","author":"Watt","year":"2019","journal-title":"Palliat Med"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"e2014639","DOI":"10.1001\/jamanetworkopen.2020.14639","article-title":"Evaluation of racial disparities in hospice use and end-of-life treatment intensity in the regards cohort","volume":"3","author":"Ornstein","year":"2020","journal-title":"JAMA Netw Open"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1920877\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T09:39:54Z","timestamp":1788341994000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1920877\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,2]]},"references-count":30,"alternative-id":["10.3389\/fmed.2026.1920877"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2026.1920877","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,2]]},"article-number":"1920877"}}